Shares of recently listed healthcare facilities company Krishna Institute of Medical Sciences (KIMS) surged over 10 per cent to Rs 1,300 on the BSE in the intra-day trade on Wednesday after the company reported a strong 57 per cent growth in consolidated profit after tax (PAT) at Rs 92.0 crore for the quarter ended June 2021 (Q1FY22) on a sequential basis.
Ebitda (earnings before interest, taxes, depreciation, and amortization) was up 41 per cent quarter on quarter (QoQ) at Rs 147.9 crore, while margins improved 200 basis points (bps) to 31.0 per cent in Q1FY22 from 29.0 per cent in Q4FY21.Consolidated revenue grew 31.6 per cent QoQ at Rs 477.50 crore from Rs 362.70 crore in previous quarter.
The company said growth during Q1FY22 was on account of contribution from ECMO and Heart & Lung Transplant program, which has doubled compared to previous quarter, and on higher occupancy of Covid patients. In addition, Vaccination revenue, RTPCR tests, Covid home care and Covid hotel packages also contributed significantly, it said.
While critical surgeries like transplants, trauma etc continued elective surgeries were impacted. However, the company have now seen the OP footfalls coming back to near normal and IP numbers are picking up too significantly. With strong push on Vaccinations by the Government, the management is confident that this should come back to near normal soon notwithstanding the sporadic spikes being reported in few parts of the country.
KIMS is one of the largest corporate healthcare groups in Andhra Pradesh and Telangana in terms of the number of patients treated and treatments offered. It operates nine multi-specialty hospitals under the 'KIMS Hospitals' brand, with an aggregate bed capacity of 3,064, including over 2,500 operational beds as of March 31, 2021.
At 11:23 am, the stock was trading at Rs 1,290, up 10 per cent on the BSE, as compared to a 0.53 per cent decline in the S&P BSE Sensex. Trading volumes on the counter rose over 20-fold with a combined 2.37 million equity shares having changed hands on the NSE and BSE.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU